Literature DB >> 1403797

Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions.

J S Leeder1, R J Riley, V A Cook, S P Spielberg.   

Abstract

Aromatic anticonvulsants such as phenytoin, phenobarbital and carbamazepine are associated with a hypersensitivity syndrome (fever, rash lymphadenopathy, hepatitis) suggestive of an immune component. We have identified immunoglobulin G antibodies in the sera of nine affected patients which recognize a 53-kD protein which is constitutively expressed and PB inducible in rat liver microsomes. No such reactivity was observed in sera from healthy controls, patients on chronic phenytoin therapy without toxicity or patients with hepatic failure not receiving anticonvulsants. Using highly purified rat hepatic cytochrome P450, P450 3A1 was identified as the major antigenic species, whereas less intense reactivity was noted with P450 2C11. P450 2C6 and 3A2 were minor antigens in some patients. In all patients, the apparent constitutive and phenobarbital-inducible expression of the antigen was a composite effect of antibodies reacting with at least two isozymes, one of which was constitutively expressed and the other PB inducible. In human liver, a 53-kD antigen was expressed to a greater extent in microsomes from a patient with a fatal hepatotoxic reaction to phenytoin compared to microsomes from normal liver or from a sulfonamide hepatitis patient. Western blotting with microsomes prepared from lymphoblastoid cell lines transfected with different human hepatic cytochromes P450 failed to identify P450s 1A1, 1A2, 2A3, 2B6, 2C9, 2D6, 2E1, 3A4 or epoxide hydrolase as the target antigen. Identification of the antigen will be important in understanding the relationship between drug metabolism and the subsequent immune response in the pathogenesis of these rare but severe forms of drug toxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1403797

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Reactive metabolites and adverse drug reactions: clinical considerations.

Authors:  Sandra R Knowles; Lori E Shapiro; Neil H Shear
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

Review 3.  Anticonvulsant hypersensitivity syndrome: incidence, prevention and management.

Authors:  S R Knowles; L E Shapiro; N H Shear
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

Review 4.  Drug-induced immunotoxicity.

Authors:  P M Dansette; E Bonierbale; C Minoletti; P H Beaune; D Pessayre; D Mansuy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Oct-Dec       Impact factor: 2.441

5.  Drug hypersensitivity to previously tolerated phenytoin by carbamazepine-induced DRESS syndrome.

Authors:  Cheol-Woo Kim; Gwang-Seong Choi; Chang-Ho Yun; Deok-In Kim
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

6.  Phenytoin-induced chronic hepatitis.

Authors:  A K Roy; H C Mahoney; R A Levine
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

7.  Detection of autoantibodies directed against human hepatic endoplasmic reticulum in sera from patients with halothane-associated hepatitis.

Authors:  N R Kitteringham; J G Kenna; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

Review 8.  In vitro analysis of metabolic predisposition to drug hypersensitivity reactions.

Authors:  R J Riley; J S Leeder
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

9.  Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions.

Authors:  Ai-Young Lee; Min-Jung Kim; Won-Young Chey; Jun Choi; Byung-Gun Kim
Journal:  Eur J Clin Pharmacol       Date:  2004-03-16       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.